8 July 2026 marked an important milestone for people affected by pulmonary fibrosis, as the Medicines and Healthcare products Regulatory Agency (MHRA) approved nerandomilast (Jascayd) as a new treatment option for adults living with Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF).
IPF and PPF are conditions where the lung tissue becomes scarred over time. As the scarring progresses, the lungs become less able to work effectively, making breathing increasingly difficult and affecting everyday life.
Nerandomilast is a new medicine that works by helping to regulate processes involved in the immune system and reducing the progression of lung tissue scarring. It is taken as an 18mg tablet by mouth twice a day and is only available with a prescription. People taking nerandomilast should always follow the advice of their doctor or pharmacist.
The MHRA approval of nerandomilast, also known by its brand name Jascayd, is a significant step forward for the pulmonary fibrosis community. It is the first new licensed medicine for pulmonary fibrosis in more than a decade and brings renewed hope that people living with these conditions may have more treatment options available in the future.
However, MHRA approval does not mean that nerandomilast is available on the NHS yet. The next stage is for the National Institute for Health and Care Excellence (NICE) to assess whether the medicine should be recommended for routine NHS use in England.
We will continue to follow the NICE assessment process closely and share further updates as they become available. For people living with pulmonary fibrosis and their families, this approval represents an important step towards improving treatment choices and supporting better outcomes in the years ahead.
Read the MHRA announcement here.
[Posted July 2026]